
Significance Neutralizing antibodies are important for immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and as therapeutics for the prevention and treatment of COVID-19. We identified high-affinity nanobodies against SARS-CoV-2 receptor-binding domain and found that nanobody cocktails consisting of two noncompeting nanobodies were able to block ACE2 engagement with RBD variants present in human populations and potently neutralize both wild-type SARS-CoV-2 and the N501Y D614G variant at low concentrations. Prophylactic administration of nanobody cocktails reduced viral loads in mice infected with the N501Y D614G SARS-CoV-2 virus, showing that nanobody cocktails are useful as prophylactic agents against SARS-CoV-2.
SARS-CoV-2, 610, COVID-19, Biological Sciences, Single-Domain Antibodies, Antibodies, Viral, Antibodies, Neutralizing, COVID-19 Drug Treatment, Mice, Animals, Humans, Angiotensin-Converting Enzyme 2, Camelids, New World
SARS-CoV-2, 610, COVID-19, Biological Sciences, Single-Domain Antibodies, Antibodies, Viral, Antibodies, Neutralizing, COVID-19 Drug Treatment, Mice, Animals, Humans, Angiotensin-Converting Enzyme 2, Camelids, New World
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 127 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 1% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 0.1% |
